Severe hemolysis in patients with prosthetic heart valves typically indicates paravalvular leak and requires individualized treatment, with surgery remaining the definitive option for severe cases.
Answers are grounded in this paper and cite their sources.
Supports tailored management of prosthetic hemolysis; leaves open need for prospective trials on less invasive options.
Hemolysis is one of the potentially serious complications of prosthetic heart valves. It is usually associated with either structural deterioration or paravalvular leak. Mild, compensated hemolysis associated with mechanical heart valves is not uncommon even in the current era. Severe hemolysis is rare, however, and usually reflects paravalvular leak. The use of transesophageal echocardiography-guided operative techniques may help prevent or minimize early postoperative paravalvular leakage. There is a gamut of available therapeutic approaches-medical, transcatheter, and surgical-to this complication and therapy should be tailored to the individual patient. Novel pharmacological agents include erythropoietin and pentoxifylline. Several reports described the feasibility of transcatheter closure of paravalvular leak with coils or devices, but their effect on hemolysis is unpredictable. Surgery remains the treatment of choice in severe cases.
No takes yet. Share an insight, caveat, or question.
Shapira et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: